Cumulative Index 1990

Volume 10

February	REPRODUCTIVE IMMUNOLOGY, pages 1–240
May	ALLERGIC INFLAMMATORY MEDIATORS AND BRONCHIAL HYPERRESPONSIVENESS I, pages 241–422
August	ALLERGIC INFLAMMATORY MEDIATORS AND BRONCHIAL HYPERRESPONSIVENESS II, pages 423–594
November	HUMAN CANCER IMMUNOLOGY I, pages 595–816

Note: Page numbers of issue and article titles are in **boldface** type.

Abortions, immunologically mediated, 20
  spontaneous, trophoblast antigens in, 39–41
Acetyl transferase, and PAF release, 536
Acrosome reaction, and antisperm antibodies, 173–176
  sperm antigens, 155–156
Acrosome-stabilizing factor, 151–152
Adenosine, in asthma, **363–372**
    biochemical pharmacology, 364
    bronchoconstriction, 364–365
      cellular mechanism, 365–368
      receptor mechanism, 365
    neural mechanisms, 369
    refractoriness, 368–369
  as inflammatory mediator, 247
β-adrenergic agents, and bronchial reactivity, **577–589**
  acute effects, 580–583
    antigens, 581–583
    exercise, 581
    histamine and methacholine, 580–581
    hyperventilation, 581
    mechanism of action, 583–584
    osmotic challenge, 581
  long-term treatment, 584–586
  measurement of change, 578–579
Adrenergic function, beta, in viral respiratory infections, 458
Air pollution, **463–481**
  indoor man-made pollutants, 473–474
    formaldehyde, 473–474
    tobacco smoke, 473
    wood smoke, 474
  natural pollutants, 474–478
    animal products, 478
    cockroach antigens, 477
    dust mites, 475–477
    mold antigens, 477–478
    pollen allergy, 478
  outdoor man-made pollutants, 465–473
    controlled human studies, 470–473
    epidemiology, 465–467
Airway, adenosine actions in asthma. See *Adenosine, in asthma.*
  epithelial cells, lipid mediator release. See *Lipid mediator release in airway epithelial cells.*
  hyperresponsiveness, **439–448**
    and anti-PAF agents, 538–539
    in asthma, 439–440
      leukotriene role, 376
    chronic airflow limitation, 445
    epidemiology, 444–445
    and inflammation, 441–444
      and activity and severity of asthma, 443–444
      causes of, 443
      changes in, 442–443
      characteristics of, 442
    measurement of, 440–441
      indirect stimuli, 441

Airway *(Continued)*
methacholine or histamine, 440–441
neutrophil role. See *Neutrophils.*
Alkaline phosphatase, placenta-specific, 83–84
Allergens, and mononuclear cell interactions, 297–298
Allergic inflammatory mediators, **241–422, 423–594**
adenosine actions in asthma, **363–372**
biochemical pharmacology, 364
bronchoconstriction, 364–365
cellular mechanism of bronchoconstriction, 365–368
neural mechanisms, 369
receptor mechanisms, 365
refractoriness, 368–369
β-adrenergic agents, **577–589**
and bronchial reactivity, 579–584
long-term treatment, 584–586
measurement of actions, 578–579
airway hyperresponsiveness and inflammation, **439–448**
asthma, 439–440
chronic airflow limitation, 445
epidemiology, 444–445
and inflammation, 441–444
measurement of, 440–441
antiasthma drugs, **483–501, 503–514**
β_2-agonists, 484–485
anticholinergic drugs, 486–488
antihistamines, 494–497
corticosteroids, 488–490
cromolyn sodium, 490–492, 503–507
nedocromil sodium, 490–492, 507–510
xanthines, 492–494
anti-PAF agents, **531–542**
functional antagonists, 537–539
PAF receptor antagonists, 531–537
atmospheric air pollution, **463–481**
indoor man-made pollutants, 473–474
natural pollutants, 474–478
outdoor man-made pollutants, 465–473
basophils, **273–282**
degranulation, 277–279
granule constituents, 276–277
in late-phase allergic reactions, 279–280
morphology, 273
phenotype, 274–276
in vitro culture, 273–274
calcium channel blockers, **515–530**
in airway functions, 516–518
calcium antagonists, in vitro effects, 518–522
in vivo effects, 522–525
calcium regulation, 515–516
clinical studies, 525–526
cellular origin of, 242–243
chemotactic factors, **355–361**
for eosinophils, 358–359
lymphocyte-directed, 359
for neutrophils, 355–358
in children, **423–437**
bronchoprovocation techniques, 428–431
causes of, 424
factors affecting reactivity, 426–428
pathophysiology of, 424–426
pharmacologic modulation, 431–434
corticosteroids, **543–557**
asthma, 543–548
clinical use, 548–551
experimental studies, 551–553
treatment aims, 544–545
cyclooxygenases, **409–418**
aspirin-induced asthma, 413
inhibition in asthma, 413–414
prostaglandin D_2, 410–411
prostaglandin E_2, 412–413
prostaglandin F_{2alpha}, 411
prostaglandin I_2, 412
thromboxane A_2, 411–412
eosinophils, **263–271**
constituents, 264–266
functions, 266–267
life cycle, 263–264
mediators and tissue damage, 267–269
structure, 263
histamine, **329–336**
antihistamines in clinical asthma, 331–334
blockade of, 332–333
bronchodilator action of antagonists, 333
cellular and tissue effects, 330–331
mast cell role, 331
immunologic reactions in asthma, **337–353**
lipid mediators in allergic reactions, 338–343
mast cell role, 343–346
lipid mediator release in airway epithelial cells, **309–318**
cyclooxygenase activity, 310–311
lipoxygenase activity, 311–313
novel epithelial cell products, 315
oxygenation pathways, 310
phospholipase activity, 313–315
substrates for oxygenation, 313
lipoxygenase, **373–381**
leukotriene B_4, 378–379
sulfidopeptide leukotrienes, 373–377
lung mononuclear cells in asthma, **295–308**
in asthma, 303
interactions with allergens, 297–298
origin and fate of, 296–297
secretory products, 298–303
mast cells, 251–262
antiasthmatic drugs, 257–258
bioactive peptide effects, 255–256
in bronchial asthma, 258–260

bronchoalveolar lavage, in extrinsic asthma, 256
and steroid therapy, 257–258
histochemical and morphologic properties, 252
hyperosmolar-induced mediator release, 254
immunologically induced mediator release, 252–254
neuropeptides in respiratory tracts, **383–407**
bradykinin, 391–392
calcitonin gene-related peptide, 388
gastrin-releasing peptide, 390–391
innervation of lower respiratory tract, 394–396
nasal mucosal innervation, 392–394
neuropeptide Y, 390
nonadrenergic noncholinergic nervous systems, 396–398
peptide histidine methionine, 389–390
physiology of, 383–386
and respiratory pathology, 398–399
sensory innervation of nasal mucosa, 392–393
tachykinins, 386–388
therapy with, 399
vasoactive intestinal peptide, 389
neutrophils, **283–293**
clinical relevance, 289–290
in IgE reaction, 284–286
in inflammatory sites, 288–289
and tissue damage, 286–288
and respiratory infections, **449–461**
microbiology, 449–451
viral infections, 452–453
mechanisms of, 453–459
T lymphocytes, **319–328**
in asthma, 322–323
bronchial inflammation, 319–322
and bronchoalveolar lavage, 323–324
therapy, 324–325
theophylline, **559–576**
clinical use, 571–573
formulations, 565–571
pharmacology, 559–565
Alloantigens, in seminal plasma, 80
trophoblast, 80–82
Allograft, fetal. See *Animal models of fetal allograft.*
Anaphylaxis, eosinophil chemotactic factor, 358
Androgens, immune system regulation by, 217–218
Animal models, in cancer immunology, **595–606**
murine melanomas, 600–601
new ideas, 601–603
tumors antigens, 595–598
UV tumor system, 598–600
of fetal allograft, **13–25**
abortions, immunologically mediated, 20
CBA/J X DBA/2 system, 21–22
local defense mechanisms, 16–17
major histocompatibility complex, 13–15
pregnancy failure, interspecies allografts, 19–20
intraspecies models, 17–19
systemic regulatory mechanisms, 15–16
granulocytes, and tumor immunity, 736–741
sperm antibodies, 176–177
Animal products, allergy to, 478
Antiasthma drugs, **483–501, 503–514**
β_2-agonists, 484–485
anticholinergic drugs, 486–488
antihistamines, 494–497
corticosteroids, 488–490
cromolyn sodium, 490–492, 503–507
nedocromil sodium, 490–492, 507–510
xanthines, 492–494
Antiasthmatic drugs, and mediator release, 257–258
Antibodies, antipaternal, 89–90
autologous human, 768–769
blocking, 85–86
monoclonal, and cell-surface antigens of human cancer, human, 620–630, 769–771
mouse, 614–620, 771–775
trophoblast antigens, 32–36
sperm. See *Sperm.*
zona pellucida, 188–189
in contraceptive vaccine, 189–194
Anticholinergic drugs, in asthma, 486–488
Antigens, and air pollution, 475–478
and bronchial reactivity, 581–583
in cancer immunology, 595–597
carbohydrate. See *Carbohydrate antigens, tumor-associated.*
cell-surface, serologic analysis. See *Serologic analysis of human cancer.*
sperm, 151–156
acrosome reaction, 155–156
in binding to zona pellucida, 152–155
caltrin, 151
sperm-immobilizing components, 152
T cell recognition of, 640–643
transplantation. See *Transplantation antigens.*
trophoblast, 82–84
Fc receptors, 84
human leukocyte, 82
placenta-specific alkaline phosphatase, 83–84
trophoblast-lymphocyte cross-reactive, 83, 95
See also *Trophoblast antigens, human.*

Antigens *(Continued)*
tumor, molecular characteristics of, **765–779**
autologous human antibodies, 768–769
human monoclonal antibodies, 769–771
mouse monoclonal antibodies, 771–775
glycolipids, 775
mucin and other high molecular glycoproteins, 773–775
protein and glycoprotein antigen, 771–773
tumor-specific transplantation antigens, 765–767
in vitro cell-mediated immune assays, 767–768
Antihistamines, in clinical asthma, 333–334
histamine receptor blocking, 494–497
Arachidonic acid, lung macronuclear cells in asthma, 300–301
Aspirin, asthma induced by, 375–376, 413
Asthma, adenosine actions. See *Adenosine, in asthma.*
and airway hyperresponsiveness and inflammation, 439–440, 443–444
anti-PAF agents, 537–539
as inflammatory disease, 241–242
aspirin-induced, 375–376, 413
bronchial, mast cell role, 258–260
bronchoalveolar lavage mast cells, 256
corticosteroid therapy. See *Corticosteroid therapy in asthma.*
cyclooxygenase inhibition, 413–414
drug therapy. See *Antiasthma drugs.*
histamine in, **329–336**
antihistamine effects, 333–334
blockade of, 332–333
bronchodilator action of antagonists, 333
immunologic reactions in, **337–353**
lipid mediators in allergic reactions, 338–343
mast cell role, 343–346
leukotrienes in airways hyperresponsiveness, 376
lung macronuclear cells, 303–304
neutrophil role. See *Neutrophils.*
and respiratory infections. See *Respiratory infections.*
sulfidopeptide leukotrienes, 373–374
T lymphocytes, 322–323
bronchoalveolar lavage, 323–324
therapy, 324–325
Autoantibodies, and pregnancy wastage, 104–105
Autoimmune diseases in pregnancy. See *Pregnancy.*
Autologous serologic typing, of cell-surface antigens of human cancer, 610–614

β_2-agonists, antiasthmatic effects, 484–485
Basal plate formation, 90–91
Basophils, **273–282**
calcium channel blocker effects, 519
degranulation, 277–279
granule constituents, 276–277
in late-phase allergic responses, 279–280
mediator release, in viral respiratory infections, 454–456
morphology, 273
phenotype, 274–276
in vitro culture, 273–274
Blood cells, peripheral, cytolytic T lymphocytes from, 648–650
Bradykinin, 391–392
as inflammatory mediator, 247
and mast cells, 255
Bronchial hyperresponsiveness. See *Allergic inflammatory mediators.*
Bronchoalveolar lavage mast cells, in asthma, 256
steroid therapy, 257–258
T lymphocytes, 323–324
Bronchoconstriction, adenosine-induced, 364–365
allergen-induced, and anti-PAF agents, 537
and calcium channel blockers, 522–525
cellular mechanisms, 365–368
receptor mechanism, 365
Bronchoprovocation techniques, 428–431

C5a, 356
Calcitonin gene-related peptide, 388
Calcium channel blockers, **515–530**
in airway functions, 516–518
glycoprotein secretion, 517
mediator release, 517
smooth muscle contraction, 518
calcium antagonists, in vitro effects, 518–522
chemical mediator release, 518–520
smooth muscle contraction, 520–522
synthesis of chemical mediators, 520
in vivo effects, 522–525
bronchoconstriction, agonist-induced, 522–523
antigen-induced, 524
exercise-induced, 525
late-phase, 524–525
mucociliary transport, 525
clinical studies, 525–526
regulation of calcium, 515–516
Calcium. See *Calcium channel blockers.*
Caltrin, 151
Cancer immunology, **595–816**
carbohydrate antigens, **781–802**
chemical and structural basis, 783–790
diagnostic application, 792–793

enzymatic basis of glycosylation, 790–792
specificity, 781–783, 792
therapeutic application, 793–798
cytokines, and tumor immunity, **747–764**
other cytokines, 758–759
tissue necrosis factor, 747–757
in transfected tumors, 757
granulocytes, and tumor immunity, **731–746**
animal tumor models, 736–741
polymorphonuclear neutrophil-induced tumor lysis, 731–736
killer cells, natural and lymphokine-activated, **663–704**
activation of by IL-2, 675–677
and cancer therapy, 684–687
defects in, risk factor for malignancy, 679–680
definitions and characteristics of, 664–665
future experimental and therapeutic efforts, 693–695
and host resistance against cancer, 677–679
immunotherapy with, 687–693
as prognostic factor, 680–683
regulation of, 671–675
and stress in patients with cancer, 683–684
in vitro assays, 665–671
macrophages, and tumor immunity, **705–729**
activation of, 707–708
tumoricidal state, 710–711
and autochthonous osteogenic sarcoma lung metastases, 716–717
clinical studies, 717–721
interaction with neoplastic cells, 708–710
liposomes containing immunomodulators, 712–716
physiologic role in homeostasis and cancer, 706–707
preclinical studies, 711–712
molecular characteristics of tumor antigens, **765–779**
autologous human antibody detection of, 768–769
and human monoclonal antibodies, 769–771
and mouse monoclonal antibodies, 771–775
tumor-specific transplantation antigens, 765–767
in vitro cell-mediated immune assays, 767–768
principles of, **595–606**
animal studies on tumor antigens, 595–598
murine melanomas, 600–601
new ideas, 601–603
UV tumor system, 598–600
serologic analysis, **607–637**
cell-surface antigens of human cancer, 610–630
autologous serologic typing, 610–614
human monoclonal antibodies, 620–630
mouse monoclonal antibodies, 614–620
cell-surface antigens of mouse tumors, 609–610
T lymphocytes, antitumor responses, **639–662**
human antitumor T cell responses, 648–657
T cell recognition and immune surveillance, 640–648
Carbohydrate antigens, tumor-associated, **781–802**
chemical and structural basis, 783–790
diagnostic application, 792–793
enzymatic basis of aberrant glycosylation, 790–792
specificity, 781–783, 792
therapeutic application, 793–798
Carbohydrates of zona pellucida, 187–188
Cell-mediated immune assays, 767–768
Cell-surface antigens. See *Serologic analysis of human cancer.*
Cellular infiltration, and anti-PAF agents, 538
Cervix, immune cells, 4
Chemotactic factors, **355–361**
and calcium channel blockers, 522
eosinophilic, 358–359
in anaphylaxis, 358
interleukin-5, 359
oligopeptides, 358
platelet-activating factor, 358–359
lung macronuclear cells in asthma, 299–300
lymphocyte-directed, 359
for neutrophils, 355–358, 740
C5a, 356
high molecular weight, 357
leukotriene B_4, 356–357
neutrophil-activating factor, 357–358
Children and infants, bronchial hyperresponsiveness, **423–437**
bronchoprovocation techniques, 428–431
causes of, 424
factors affecting reactivity, 426–428
pathophysiology, 424–426
pharmacologic modulation, 431–434
Chloroquine, in pregnancy, 129
Cholinergic reflex bronchospasm, 458–459
Chromosome map, 618–619
Clones of cytolytic T lymphocytes, 652–654

Clones of cytolytic T lymphocytes *(Continued)*
immunoselection with, 654–655
Cockroach antigens, 477
Colony stimulating factor, and PMN-induced tumor lysis, 736
during pregnancy, 72–73
Complement peptides, and mast cells, 255–256
Contraceptive vaccine, and zona pellucida antibodies, 189–194
Corticosteroids, inhaled, in asthma, 488–490, **543–557**
acute attacks, 545
administration route, 549
compound type, 548
dosage, 548–549
end point of use, 549
oral treatment, 549
resistance to, 549
experimental use, 551–553
early responses, 551–552
inflammatory cells, 552–553
late asthmatic responses, 551
seasonal asthma, 552
long-term treatment, 545–548
and lung function and hyperresponsiveness, 549–551
treatment aims, 544–545
in pregnancy, 128
Cromolyn sodium, in asthma, 490–492
chronic dose studies, 505–506
mechanism of action, 503–504
nonspecific bronchial hyperresponsiveness, 506–507
single dose (acute) studies, 504–505
Cultured cell map, and cell-surface antigens of human cancer, 616
Cyclooxygenase mediators, **409–418**
aspirin-induced asthma, 413
inhibition in asthma, 413–414
and lipid mediator release, 310–311
prostaglandin D_2, 410–411
prostaglandin E_2, 412–413
prostaglandin F_{2alpha}, 411
prostaglandin I_2, 412
thromboxane A_2, 411–412
Cystic disease of ovary, 210
Cytokines, in allergic reactions, 342–343
maternal allogeneic responses, 88–89
recombinant, and PMN-induced tumor lysis, 735–736
and tumor immunity, **747–764**
other cytokines, 758–759
tissue necrosis factor, 747–757
in normal and malignant cells in vitro, 747–748
and hemorrhagic necrosis and shock, 751–756
resistance mechanisms, 749–750
resistance to in vitro and in vivo, 751
T cell-mediated immunity, 756–757
and tumor cell killing by macrophages and monocytes, 748–749
tumor growth in vivo, 750–751
in transfected tumors, 757
Cytolytic T cells, antitumor, 648–655
Cytotoxicity, and antitumor function of PMNs, 737–739
and PMN-induced tumor lysis, nonoxidative, 733–734
oxidative, 731–733
in pregnancy, 128

Decidua, immune cells, 5
and maternofetal interface immunoregulation, 53–59
Disease markers, trophoblast antigens, 36–37
Dust mites, and air pollution, 475–477

Edema, and anti-PAF agents, 537–538
Egg plasma membrane, and sperm antigens, 156–158
Embryo as graft, 49–51
Endocrine system, and immune system, **215–233**
hypothalamic-pituitary-gonadal thymic axis, 227–230
pituitary hormones, 220–224
gonadotropins, 222
growth hormones, 223–224
prolactin, 223
steroid hormones, 216–220
androgens, 217–218
estrogens, 216–217
glucocorticoids, 219–220
progestins, 218–219
thymic hormones, 224–227
Endometrium, immune cells, 5
Eosinophils, **263–271**
chemotactic factors, 358–359
in anaphylaxis, 358
interleukin-5, 359
oligopeptides, 358
platelet-activating factor, 358–359
constituents, 264–266
functions, 266–267
life cycle, 263–264
mediators, and tissue damage, 267–269
structure, 263
Epidemiology, of air pollution, 465–467
of airway hyperresponsiveness and inflammation, 444–445
Epididymal sperm granuloma, 206
Epithelium, airway, in viral respiratory infections, 459

lipid mediator release. See *Lipid mediator release in airway epithelial cells.*
Estrogens, immune system regulation by, 216–217
Exercise, and bronchial reactivity, 581
bronchoconstriction induced by, 525

Fallopian tubes, immune cells, 6
Fc receptors, 84
antibodies, 86–87
Female reproductive tract, immune cells, 3–7
cervix, 4
decidua, 5
endometrium, 5
fallopian tubes, 6
ovary, 6–7
peritoneal cavity, 7
vagina, 3–4
Fertility, and immunology of male reproductive tract, 1–3
Fertilization antigen 1, 157–158
sperm antigens. See *Sperm.*
Fetomaternal interface, lymphokine actions, 68
Fetus, allograft. See *Animal models of fetal allograft.*
survival, suppressor cell role, 59–60
wastage and nonrecognition, **79–102**
alloantigens, in seminal plasma, 80
in trophoblast, 80–82
immunogenetics, 91–94
immunotherapy, 94–95
paternal leukocyte immunization, 94–95
third-party leukocyte immunization, 94
trophoblast-microvilli infusion, 95
vaginal suppositories, 95
maternal allogeneic responses, 85–91
antibodies to Fc receptors, 86–87
antipaternal antibodies and anti-idiotype network, 89–90
blocking antibodies, 85–86
cytokines and growth factors, 88–89
implantation and basal plate formation, 90–91
suppressor cells, 87–88
trophoblast antigens, 82–84
Fc receptors, 84
human leukocyte, 92
placenta-specific alkaline phosphatase, 83–84
trophoblast-lymphocyte cross-reactive, 83
Formaldehyde, air pollution by, 473–474
Functional map, and cell-surface antigens of human cancer, 619–620

Gamete interaction, and sperm antibodies, 172
Gastrin-releasing peptide, 390–391
Glucocorticoids, immune system regulation by, 219–220
Glycolipid antigens, 775
Glycoproteins, and mouse monoclonal antibodies, 771–773
and calcium channel blockers, 517
Glycosylation, and carbohydrate antigens, 790–792
Gold therapy in pregnancy, 128–129
Gonadotropins, immune system regulation by, 222
Granules, of basophils, 276–277
Granulocytes, and tumor immunity, **731–746**
animal tumor models, 736–741
antitumor function of PMNs, 737–739
PMN in tumors, 736–737
sequential waves of responses, 740–741
PMN-induced tumor lysis, 731–736
nonoxidative cytotoxins, 733–734
oxidative lysis, 731–733
and recombinant cytokines, 735–736
triggering signals, 734–735
Growth, intrauterine, hypertension and immune system, **109–115**
Growth factors, maternal allogeneic responses, 88–89
Growth hormone, immune system regulation by, 223–224

Hemorrhagic necrosis, and tissue necrosis factor, 751–756
Histamine, **329–336**
in asthma, 331–332
histamine blockade, 332–333
antihistamine effects, 333–334
and bronchial reactivity, 580–581
bronchodilator action of antagonists, 333
cellular and tissue effects, 330–331
as inflammatory mediator, 243–244
mast cell role, 331
measurement of airway responsiveness, 440–441
Histochemistry, of mast cells, 252
HIV (human immunodeficiency virus) infection, **133–147**
clinical disease, 138–140
diagnosis, 136–138
enzyme-linked immunosorbent assay (ELISA), 136–137
polymerase chain reaction, 137–138
pathogenesis, 134–136
and pregnancy, 140–144
therapy, 144–145
Homeostasis, macrophage role, 706–707

Human leukocyte antigens, 82
Hypertension, and intrauterine growth retardation, **109–117**
Hyperventilation, and bronchial reactivity, 581
Hypothalamic-pituitary-gonadal-thymic axis, 227–230

IgE antibodies, in viral respiratory infections, 453–454
Immune cells, in reproductive tissues, **1–12**
  in female, 3–7
  in male, 1–3
  significance of, 7–8
Immune surveillance against tumors, 644–648
Immunogenetics, fetal wastage and nonrecognition, 91–94
Immunoglobulin, surface-bound, sperm antibodies, 177–178
  enzymatic degradation, 180–181
Immunoglobulin E, and neutrophil migration, 284–286
Immunologic reactions in asthma. See *Asthma*.
Immunotherapy, for fetal wastage and nonrecognition, 94–95
  with natural and lymphokine-activated killer cells, 687–693
Implantation, and basal plate formation, 90–91
Infertility, and hypospermatogenesis, 204–205
  zona pellucida antibodies, 188–189
Inflammation, and airway hyperresponsiveness, 441–444
  activity and severity of asthma, 443–444
  causes of, 443
  changes in, 442–443
  characteristics of, 442
  allergic, anti-PAF agents, 537–539
  asthmatic bronchial, and activated T lymphocytes, 319–322
  corticosteroid therapy, 552–553
  neurogenic, 247
  neutrophil removal, 288–289
Inflammatory mediators, 243–247
  adenosine, 247
  bradykinin, 247
  histamine, 243–244
  leukotrienes, 244–245
  platelet-activating factor, 246–247
  prostaglandins, 245–246
  See also *Allergic inflammatory mediators*.
Innervation, of lower respiratory tract, 394–396
  of nasal mucosa, 392–394
Interferon, and PMN-induced tumor lysis, 735
Interleukin-1, and PMN-induced tumor lysis, 736
  during pregnancy, 69–70
Interleukin-2, and killer cells, natural and lymphokine-activated, 675–677
  during pregnancy, 70–72
Interleukin-3, 344–345
Interleukin-4, 345
  and interleukin-5, during pregnancy, 73–75
Interleukin-5, 345–346
  eosinophil chemotactic factor, 359
Interleukin-6, 346

Killer cells, natural and lymphokine-activated, **663–704**
  and cancer therapy, 684–687
  defects in, risk factor for malignancy, 679–680
  definitions and characteristics of, 664–665
  future experimental and therapeutic efforts, 693–695
  and host resistance against cancer, 677–679
  IL-2 activation of, 675–677
  immunotherapy with, 687–693
  prognostic factor in cancer patients, 680–683
  regulation of, 671–675
  and stress in cancer patients, 683–684
  in vitro assays for, 665–671

Leukocyte immunization, paternal, 95
  third-party, 94
Leukotriene B_4, 356–357
  biologic activity, 378
  biosynthesis, 378–379
Leukotrienes, 340–342
  as inflammatory mediator, 244–245
Lipid mediators, in airway epithelial cells, **309–318**
  cyclooxygenase, 310–311
  lipoxygenase, 311–313
  novel epithelial cell products, 315
  oxygenation pathways, 310
  phospholipase, 313–315
  substrates for oxygenation, 313
  in allergic reactions, 338–343
  cytokines, 342–343
  leukotrienes, 340–342
  platelet-activating factor, 339–340
Liposomes, and immunomodulators. See *Macrophages, and tumor immunity*.
  and macrophage interaction, 711–712

MTP-PE encapsulated in, Phase I trial, 718–721
Lipoxygenase mediators, **373–381**
leukotriene B_4, 378–379
and lipid release, 311–313
sulfidopeptide leukotrienes, 373–377
in airway hyperesponsiveness in asthma, 376
aspirin-induced asthma, 375–376
in asthma, 373–374
potency, 374–375
site selectivity of hyperresponsiveness, 375
Lung, autochthonous canine osteogenic sarcoma metastases, 716–717
calcium channel blocker effects, 519–520
corticosteroid effects, 549–551
mononuclear cells. See *Mononuclear cells, of lung.*
Lupus anticoagulant, 104
Lupus erythematosus, systemic, and pregnancy, 124–125
Lymphocytes, chemotactic factors, 359
in semen, 2–3
T. See *T lymphocytes.*
Lymphokine-activated killer cells. See *Killer cells, natural and lymphokine-activated.*
Lymphokines in pregnancy, **65–77**
colony-stimulating factors, 72–73
at fetomaternal interface, 68
functions of, 65–68
interleukin-1, 69–70
interleukin-2, 70–72
interleukin-4 and interleukin-5, 73–75

M29 antigen, 157
M42 antigen, 155–156
Macrophages, in semen, 2–3
and tumor immunity, **705–729**
activation to tumoricidal state, 707–708
systemic, 710–711
and autochthonous canine osteogenic sarcoma lung metastases, 716–717
clinical studies, 717–721
colorectal cancer, 717–718
osteogenic sarcoma, 718
phase I trial of liposome-encapsulated MTP-PE in cancer patients, 718–721
and liposomes containing immunomodulators, 712–716
and mouse melanoma metastases, 714–716
murine macrophage activation by, 712–714
in vitro activation of human monocytes, 712
and neoplastic cell interaction, 708–710
physiologic role in homeostasis and cancer, 706–707
preclinical studies, 711–712
tissue necrosis factor, 748–749
Major basic protein, as trophoblast antigen, 38–39
Major histocompatibility complex antigens, trophoblast, 28–32
fetal allograft, 13–15
Male reproductive tract, immune cells in, 1–3
lymphocytes and macrophages in semen, 2–3
white blood cell factors, 3
Mast cells, **251–262**
antiasthmatic drugs, and mediator release, 257–258
bioactive peptide effects, 255–256
bradykinin, 255
complement peptides, 255–256
sensory neuropeptides, 254–255
in bronchial asthma, 258–260
bronchoalveolar lavage, in extrinsic asthma, 256
and steroid therapy, 257258
calcium channel blocker effects, 518–519
and histamine action, 331
histochemical and morphologic properties, 252
in immune response, 343–346
interleukin-3, 344–345
interleukin-4, 345
interleukin-5, 345–346
interleukin-6, 346
mediator release, hyperosmolar-induced, 254
immunologically induced, 252–254
Maternofetal interface, immunoregulation of, **49–64**
decidua role, 53–59
suppressor cells
and fetal survival, 59–60
hormone-dependent, 56–58
trophoblast-dependent, 58–59
trophoblast-independent, 54–56
embryo as graft, 49–51
local versus systemic suppression, 51–52
lymphokine actions, 68
trophoblast role, 52–53
uterine properties, 52
Mediator release, and antiasthmatic drugs, 257–258
by mast cells, hyperosmolar-induced, 254
immunologically induced, 252–254
lipid, in airway epithelial cells. See *Lipid mediators.*
and lung macronuclear cells, 302–303
See also *Allergic inflammatory mediators.*

Melanomas, metastases, and liposomes containing immunomodulators, 714–716
murine, 600–601
Metastasis, 714–717
lung, autochthonous canine osteogenic sarcoma, 716–717
melanoma, and activated macrophages, 714–716
Methacholine, and bronchial reactivity, 580–581
measurement of airway responsiveness, 440–441
Mold antigens, 477–478
Mononuclear cells, of lung, **295–308**
and allergen interactions, 297–298
arachidonic acid products, 300–301
in asthma, 303–304
origin and fate of, 296–297
secretory products, 298–303
arachidonic acid products, 300–301
chemotactic factors, 299–300
and mediator release from other lung cells, 302–303
mucus-stimulating factor, 301–302
Morphology, of basophils, 273
of mast cells, 252
MTP-PE, liposome-encapsulated, phase I trial in cancer patients, 718–721
Mucin antigens, 773–775
Mucociliary transport, 525
Mucus-stimulating factor, 301–302
Muscle, smooth, calcium channel blocker effect on contraction, 518, 520–522
Myasthenia gravis, and pregnancy, 125–127

Nasal mucosal innervation, 392–394
parasympathetic, 393–394
sensory, 392–393
sympathetic, 394
Natural killer cells. See *Killer cells, natural and lymphokine-activated.*
Nedocromil sodium, in asthma, 490–492
bronchial hyperresponsiveness in humans, 508–510
mechanism of action, 507–508
Neuropeptide Y, 390
Neuropeptides, **383–407**
atrial natriuretic peptide, 391
bradykinin, 391–392
calcitonin gene-related peptide, 388
galanin, 391
gastrin-releasing peptide, 390–391
innervation, of lower respiratory tract, 394–396
nasal mucosa innervation, 392–394
parasympathetic, 393–394
sensory, 392–393
sympathetic, 394
neuropeptide Y, 390
nonadrenergic noncholinergic nervous systems, 396–398
peptide histidine methionine, 389–390
physiology of, 383–386
and respiratory pathology, 398–399
sensory, and mast cells, 254–255
tachykinins, 386–388
therapy with, 399
vasoactive intestinal peptide, 389
Neutrophil-activating factor, 357–358
Neutrophils, **283–293**
and calcium channel blockers, 519
chemotactic factors, 355–358
C5a, 356
high molecular weight, 357
leukotriene B_4, 356–357
neutrophil-activating factor, 357–358
clinical relevance, 289–290
in IgE reaction, 284–286
in inflammatory sites, 288–289
and tissue damage, 286–288
Nonsteroidal anti-inflammatory agents in pregnancy, 128

Oligopeptides, eosinophil, 358
Orchitis, "allergic", 205–206
epididymal sperm granuloma, 206
experimental autoimmune, 199–204
from neonatal thymectomy, 203
postvasectomy, 204
granulomatous, 205
and viral infections, 205
Osmotic challenge, and bronchial reactivity, 581
Ovary, autoimmune diseases, 206–210
immune cells, 6–7
Oxidative lysis, and PMN-induced tumor lysis, 731–733
Oxygenation, and lipid mediator release, 310
substrates for, 313

Penicillamine, in pregnancy, 128
Peptide histidine methionine, 389–390
Peritoneal cavity, immune cells, 7
PH-20, 153–154
PH-30, 157
Phenotype of basophils, 274–276
Phospholipase A_2 inhibitors, and PAF release, 534–535
Phospholipase, and lipid mediator release, 313–315

Pituitary hormones, and immune system, 220–224
Platelet-activating factor (PAF), **531–542**
in allergic reactions, 339–340
eosinophil chemotactic factor, 358–359
functional antagonists, 537–539
airway hyperresponsiveness, 538–539
allergen-induced bronchoconstriction, 537
cellular infiltration, 538
edema, 537–538
as inflammatory mediator, 246–247
inhibition of release, 534–537
acetyl transferase inhibitors, 536
other agents, 536–537
phospholipase A_2 inhibitors, 534–535
receptor antagonists, 531–537
naturally occurring, 534
PAF analogues, 531–533
synthetic antagonists, 533–534
Pollen allergy, 478
Polymorphonuclear neutrophils, and tumor lysis, 731–736
See also *Granulocytes, and tumor immunity.*
Pregnancy, autoimmune diseases, **119–131**
immune thrombocytopenic purpura, 119–121
immunologic and anti-inflammatory therapy, 127–129
chloroquine, 129
corticosteroids, 128
cytotoxic agents, 128
gold, 128–129
nonsteroidal anti-inflammatory agents, 128
penicillamine, 128
salicylates, 127–128
myasthenia gravis, 125–127
rheumatoid arthritis, 123–124
systemic lupus erythematosus, 124–125
thyroid disease, 122–123
fetal wastage, with abnormal autoimmunity, **103–108**
autoantibody abnormalities, 104–105
lupus anticoagulant, 104
reproductive autoimmune failure syndrome, 106
treatment, 105–106
and nonrecognition, **79–102**
alloantigens, 80–82
immunogenetics, 91–94
immunotherapy, 94–95
maternal allogeneic responses, 84–91
trophoblast antigens, 82–84
HIV infection, 140–144
immunologic failure, animal models, 17–20
lymphokines. See *Lymphokines in pregnancy.*
Premature ovarian failure, 209–210
Proacrosin, 154–155
Progestins, immune system regulation by, 218–219
Prolactin, immune system regulation by, 223
Prostaglandin D_2, 410–411
Prostaglandin E_2, 412–413
Prostaglandin F_{2alpha}, 411
Prostaglandin I_2, 412
Prostaglandins, as inflammatory mediators, 245–246
Protein, antigens, and mouse monoclonal antibodies, 771–773
of zona pellucida, 186–187

Rabbit sperm autoantigen, 155
Receptors, transferrin, as trophoblast antigens, 37–38
Reproductive immunology, **1–240**
animal models of fetal allograft, **13–25**
CBA/J X DBA/2 system, 21–22
immunologically mediated abortions, 20
interspecies allografts and pregnancy failure, 19–20
intraspecies models of pregnancy failure, 17–19
local defense mechanisms, 16–17
major histocompatibility complex, 13–15
systemic regulatory mechanisms, 15–16
autoimmune disease in pregnancy, **119–131**
anti-inflammatory agents and immunosuppressants, 127–129
autoimmune thyroid disease, 122–123
immune thrombocytopenic purpura, 119–121
myasthenia gravis, 125–127
rheumatoid arthritis, 123–124
systemic lupus erythematosus, 124–125
autoimmune failure syndrome, 106
fetal wastage and nonrecognition, **79–102**
alloantigen sites, 80–82
immunogenetics, 91–94
immunotherapy, 94–95
maternal allogeneic responses, 84–91
trophoblast antigens, 82–84
HIV (human immunodeficiency virus) infection, **133–147**
clinical disease, 138–140
diagnosis, 136–138
pathogenesis, 134–136
in pregnancy, 140–144
therapy, 144–145
hypertension and intrauterine growth retardation, **109–117**
background, 109–110

Reproductive immunology *(Continued)*
fetal growth, 110–112
and immune system, 112–115
immune cells in reproductive tissues, **1–12**
in female, 3–7
in male, 1–3
significance of, 7–8
lymphokines in pregnancy, **65–77**
colony-stimulating factors, 72–73
at fetomaternal interface, 68
function of, 65–68
interleukin-1, 69–70
interleukin-2, 70–72
interleukin-4 and interleukin-5, 73–75
of maternofetal interface, **49–64**
decidua role, 53–59
embryo as graft, 49–51
local versus systemic suppression, 51–52
suppressor cells and fetal survival, 59–60
trophoblast role, 52–53
uterine properties, 52
orchitis and oophoritis, autoimmune, **199–213**
ovarian autoimmune diseases, 206–210
testicular autoimmune diseases, 199–206
pregnancy wastage with abnormal autoimmunity, **103–108**
autoantibody abnormalities, 104–105
lupus anticoagulant, 104
reproductive autoimmune failure syndrome, 106
treatment, 105–106
sperm antibodies, **165–184**
acrosome reaction, 173–176
animal models, 176–177
antigens to, 167–168
clinical assessment, 166–167
enzymatic degradation of immunoglobulins, 180–181
and sperm function, 168–172
surface-bound immunoglobulins, 177–178
treatment, 178–180
sperm antigens in fertilization, **149–164**
acrosome reaction, 155–156
binding to zona pellucida, 152–155
cellular sequence for fertilizing sperm, 150–151
fusion with egg plasma membrane, 156–158
sperm-coating antigens, 151–152
zona pellucida penetration, 156
trophoblast antigens, human, **27–48**
amplification of responses to, 41–42
disease markers, 36–37
major basic protein, 38–39
major histocompatibility antigens, 28–30
class I gene expression, 31–32
monoclonal antibodies, 32–36
in spontaneous abortions, 39–41
transferrin and transferrin receptors, 37–38
trophoblast subpopulations, 27–28
zona pellucida antigens, **185–197**
antibodies, in contraceptive vaccine development, 189–193
in infertility, 188–189
biochemical composition, 186
carbohydrates of, 187–188
formation of, 188
proteins of, 186–187
Resistance against cancer, role of natural and lymphokine-activated killer cells, 677–679
tissue necrosis factor, 749–750
Respiratory infections, and asthma, **449–461**
microbiology of, 449–451
bacteria, 451
viruses, 449–451
viral infections, 452–459
mechanisms of, 453–459
β-adrenergic function, 458
basophil mediator release, 454–456
cholinergic reflex bronchospasm, 458–459
epithelial injury, 459
IgE antibody production, 453–454
rhinovirus effects, 456
pathogenesis of, 452–453
Respiratory tract, neuropeptides in. See *Neuropeptides.*
Rheumatoid arthritis, and pregnancy, 123–124
Rhinovirus, and airway hyperresponsiveness and asthma, 456
Risk factors for malignancy, defects in natural and lymphokine-activated killer cells, 679–680

Salicylates for autoimmune diseases, 127–128
Semen, alloantigens, 80
lymphocytes and macrophages, 2–3
Serologic analysis of human cancer, **607–637**
cell-surface antigens of human cancer, 610–630
autologous serologic typing, 610–614
human monoclonal antibodies, 620–630
mouse monoclonal antibodies, 614–620
chromosome map, 618–619
cultured cell map, 616
functional map, 619–620
tissue map, 616–618

cell-surface antigens of mouse tumors, 609–610
Shock, and tissue necrosis factor, 751–756
Sperm, antibodies, **165–184**
acrosome reaction, 173–176
animal models, 176–177
antigens, 167–168
clinical tests, 166–167
and gamete interaction, 172
sperm transport, 168–172
surface-bound immunoglobulins, 177–178
enzymatic degradation, 180–181
treatment of immunity, 178–180
antigens in fertilization, **149–164**
acrosome reaction, 155–156
binding to zona pellucida, 152–155
cellular sequence of fertilization, 150–151
fusion with egg plasma membrane, 156–158
sperm-coating antigens, 151–152
zona pellucida penetration, 156
white blood cell factors, 3
Steroids, and bronchoalveolar lavage mast cells, 257
immune system regulation by, 216–220
Stress in cancer patients, and natural killer cells, 683–684
Sulfidopeptide leukotrienes. See *Lipoxygenase mediators.*
Suppressor cells, maternal allogeneic responses, 87–88
and maternofetal interface immunoregulation, 54–60
and fetal survival, 59–60
hormone-dependent, 56–58
trophoblast-dependent, 58–59
trophoblast-independent, 54–56

T lymphocytes, **319–328**
activated, and asthmatic bronchial inflammation, 319–322
antitumor responses, **639–662**
human antitumor T cell responses, 648–657
antitumor cytolytic T cells, 648–655
cytolytic T lymphocyte clones, 652–654
from peripheral blood cells, 648–650
from tumor-infiltrating lymphocytes, 650–651
immunoselection with clones, 654–655
specificity of, 651–652
in vivo relevance, 655
noncytolytic responses, 655–657
tumor escape from, 657
recognition and immune surveillance, 640–648
antigen recognition by T cells, 640–643
immune surveillance against tumors, 643–648
T cell-mediated immune surveillance, 643–645
transplantation antigens on spontaneous tumors, 645–648
tumor-specific transplantation antigens, 643
in asthma, 322–323
bronchoalveolar lavage, 323–324
therapy, 324–325
and tissue necrosis factor, 756–757
Tachykinins, 386–388
Testis, autoimmune diseases, 199–206
Theophylline, w559–576
clinical use, 571–573
formulations, 565–571
pharmacology, 559–565
Thrombocytopenic purpura, immune, in pregnancy, 119–121
Thromboxane A_2, 411–412
Thymectomy, neonatal, and autoimmune orchitis, 203
and autoimmune oophoritis, 206–207
Thymic hormones, and immune system, 224–227
Thyroid disease, and pregnancy, 122–123
Tissue damage, eosinophil mediators, 267–269
neutrophil role, 286–288
Tissue map, 616–618
Tissue necrosis factor. and PMN-induced tumor lysis, 735–736
See also *Cytokines, and tumor immunity.*
Tobacco smoke, air pollution by, 473
Transferrin, and receptors, as trophoblast antigens, 37–38
Transplantation antigens, tumor-specific, 643, 765–767
on spontaneous tumors, 645–648
Trophoblast antigens, human, **27–48**, 82–84
amplification of responses, 41–42
chorionic, 81–82
disease markers, 36–37
endovascular, 81
interstitial, 80–81
lymphocyte cross-reactive, 83
major basic protein, 38–39
major histocompatibility complex antigens, 28–30
class I gene expression, 31–32
monoclonal antibodies, 35–36
and maternofetal interface immunoregulation, 52–53
and microvilli infusion, 95

Trophoblast antigens *(Continued)*
monoclonal antibodies, 32–35
in spontaneous abortion, 39–41
subpopulations of trophoblast, 27–28
transferrin and transferrin antigens, 37–38
villous, 80
Trypsin inhibitor-sensitive site, 153

Ultraviolet radiation, tumor system, 598–600
Uterus, and maternofetal interface immunoregulation, 52

Vaccine, contraceptive, and zona pellucida antibodies, 187–194
Vagina, immune cells, 3–4
suppositories with seminal plasma trophoblast lymphocyte cross-reactive antigens, 95
Vasectomy, and autoimmune orchitis, 204
Vasoactive intestinal peptide, 389

White blood cells, and male fertility and sperm function, 3
Winn assays, and antitumor function of PMNs, 739
Wood smoke, and air pollution, 474

Xanthines, in asthma, 492–494

Zona pellucida, **185–197**
antibodies, and contraceptive vaccine, 189–194
in infertility, 188–189
biochemical composition, 186
carbohydrates, 187–188
formation of, 188
immunization, and ovarian diseases, 209
proteins of, 186–187
and sperm antigens, 152–155, 156